Mount Sinai continues to gain global recognition for its groundbreaking work with ketamine and post-traumatic stress disorder (PTSD), publishing studies in 2021 which showed for the first time the effectiveness of repeat ketamine infusions for treating PTSD, and changes in the brain’s neurocircuitry that may be at the root of the improvement. That seminal work is paving the way for additional research to determine if the robust response seen in patients with chronic PTSD can be maintained over longer periods, such as months or potentially years.